Drug Profile
NRD 135S E1
Alternative Names: E1; NRD E1; NRD.E1; NRD135S; NRD135S-E1; NRD135S.E1; NRD135SE.1Latest Information Update: 30 Sep 2022
Price :
$50
*
At a glance
- Originator Novaremed
- Class Alcohols; Amides; Anti-inflammatories; Benzene derivatives; Non-opioid analgesics; Phenols; Small molecules
- Mechanism of Action Lyn protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuropathic pain
Most Recent Events
- 16 Sep 2022 Phase-II clinical trials in Neuropathic pain in USA (PO) (NCT05480228)
- 21 Jul 2022 NRD 135S E1 licensed to NeuroFront for peripheral neuropathy and neuropathic pain in China, Hong Kong, Macau, Taiwan and Singapore
- 23 Jun 2022 Efficacy and safety data from a phase II trial in Neuropathic pain released by Novaremed